Latest Ratios: P/E Ratio 31.0x · EV/EBITDA 19.3x · ROE 17.8%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1B | $1.7B | $1.9B | $1.3B | $903M | $535M | $353M | $373M | $223M | $204M | $185M |
| Enterprise Value | $2.2B | $1.9B | $2.1B | $1.4B | $967M | $608M | $331M | $372M | $245M | $166M | $155M |
| P/E Ratio → | 31.02 | 25.32 | 32.26 | 29.51 | 21.63 | 33.62 | 26.33 | 18.86 | 15.56 | 22.06 | 23.14 |
| P/S Ratio | 3.49 | 2.87 | 3.77 | 3.31 | 2.55 | 2.59 | 1.97 | 1.88 | 1.17 | 1.38 | 1.27 |
| P/B Ratio | 5.01 | 4.09 | 5.55 | 4.63 | 3.80 | 2.75 | 1.99 | 2.30 | 1.59 | 1.65 | 1.64 |
| P/FCF | 26.65 | 21.94 | 33.43 | 42.95 | 227.90 | 60.13 | 17.06 | 14.65 | 14.04 | 28.78 | 88.17 |
| P/OCF | 22.90 | 18.85 | 28.58 | 32.05 | 50.91 | 37.43 | 14.08 | 11.94 | 10.47 | 11.68 | 19.71 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.10 | 4.16 | 3.41 | 2.73 | 2.95 | 1.84 | 1.88 | 1.29 | 1.12 | 1.06 |
| EV / EBITDA | 19.34 | 16.13 | 21.92 | 19.77 | 14.38 | 20.53 | 13.22 | 11.32 | 8.93 | 9.58 | 8.65 |
| EV / EBIT | 24.25 | 20.22 | 25.85 | 23.73 | 17.43 | 28.63 | 20.20 | 15.30 | 11.87 | 14.11 | 12.49 |
| EV / FCF | — | 23.64 | 36.81 | 44.28 | 244.02 | 68.36 | 15.99 | 14.62 | 15.42 | 23.42 | 73.64 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.3% | 28.3% | 29.1% | 28.1% | 25.5% | 24.8% | 24.9% | 27.2% | 25.4% | 24.0% | 23.7% |
| Operating Margin | 15.3% | 15.3% | 16.0% | 14.4% | 15.7% | 10.3% | 9.3% | 12.5% | 10.3% | 7.9% | 8.4% |
| Net Profit Margin | 11.3% | 11.3% | 11.7% | 11.2% | 11.8% | 7.7% | 7.5% | 10.0% | 7.5% | 6.2% | 5.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 17.8% | 17.8% | 18.8% | 17.2% | 19.3% | 8.6% | 7.9% | 13.1% | 10.8% | 7.8% | 7.4% |
| ROA | 10.6% | 10.6% | 11.4% | 11.5% | 11.7% | 5.9% | 6.8% | 10.4% | 8.7% | 6.9% | 6.4% |
| ROIC | 12.7% | 12.7% | 14.1% | 13.8% | 14.6% | 7.5% | 7.9% | 11.4% | 11.9% | 10.4% | 11.6% |
| ROCE | 16.1% | 16.1% | 18.0% | 17.3% | 17.9% | 8.8% | 9.3% | 14.5% | 13.2% | 9.5% | 10.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.36 | 0.36 | 0.60 | 0.16 | 0.29 | 0.43 | 0.01 | 0.02 | 0.18 | — | 0.01 |
| Debt / EBITDA | 1.33 | 1.33 | 2.15 | 0.67 | 1.02 | 2.85 | 0.09 | 0.09 | 0.92 | — | 0.05 |
| Net Debt / Equity | — | 0.32 | 0.56 | 0.14 | 0.27 | 0.38 | -0.12 | -0.00 | 0.16 | -0.31 | -0.27 |
| Net Debt / EBITDA | 1.16 | 1.16 | 2.01 | 0.59 | 0.95 | 2.47 | -0.88 | -0.02 | 0.80 | -2.19 | -1.71 |
| Debt / FCF | — | 1.70 | 3.38 | 1.32 | 16.12 | 8.23 | -1.07 | -0.03 | 1.38 | -5.36 | -14.53 |
| Interest Coverage | 9.42 | 9.42 | 10.06 | 15.79 | 20.08 | 544.72 | 197.18 | 36.08 | 15.65 | 235.26 | 179.51 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.68 | 2.68 | 2.56 | 2.48 | 2.08 | 2.25 | 4.75 | 3.17 | 2.69 | 7.55 | 7.31 |
| Quick Ratio | 1.52 | 1.52 | 1.41 | 1.28 | 1.12 | 1.39 | 3.52 | 2.08 | 1.75 | 6.26 | 5.83 |
| Cash Ratio | 0.27 | 0.27 | 0.18 | 0.09 | 0.08 | 0.29 | 1.60 | 0.22 | 0.16 | 3.82 | 3.28 |
| Asset Turnover | — | 0.91 | 0.80 | 0.99 | 0.94 | 0.62 | 0.88 | 1.05 | 1.00 | 1.07 | 1.14 |
| Inventory Turnover | 4.98 | 4.98 | 4.09 | 4.10 | 4.92 | 4.64 | 7.23 | 7.90 | 7.26 | 8.73 | 7.88 |
| Days Sales Outstanding | — | 53.42 | 64.88 | 59.98 | 56.86 | 69.67 | 53.78 | 53.22 | 54.28 | 52.79 | 53.07 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.2% | 3.9% | 3.1% | 3.4% | 4.6% | 3.0% | 3.8% | 5.3% | 6.4% | 4.5% | 4.3% |
| FCF Yield | 3.8% | 4.6% | 3.0% | 2.3% | 0.4% | 1.7% | 5.9% | 6.8% | 7.1% | 3.5% | 1.1% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | 0.3% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% | 0.3% |
| Shares Outstanding | — | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $7M | $7M | $7M |
Customer concentration and OEM reliance
Based on current market data, UFPT trades at a forward P/E of 27.34, which suggests that investors are pricing in significant future earnings expansion despite the recent deceleration in top-line growth observed in the most recent quarterly filings compared to the company's historical performance.
The current P/E multiple appears elevated relative to the company's recent earnings volatility, implying that the market is assigning a premium for its specialized role in the MedTech supply chain. Investors should monitor whether this valuation remains sustainable if the current trend of decelerating revenue growth persists, as the PEG ratio of 0.79 may be masking underlying risks related to margin compression.
As reported in financial statements, UFPT's ROIC has trended downward to 3.1% in 2026Q1, reflecting the dilutive impact of recent inorganic growth strategies on the company's ability to generate returns on its expanding asset base compared to the higher efficiency levels seen in previous periods.
The decline in ROIC suggests that the capital deployed for acquisitions has yet to yield the expected operational synergies, potentially due to the integration challenges inherent in scaling specialized manufacturing. This trend warrants further investigation into whether the company's return profile will recover as these acquired units reach full operational maturity.
According to recent quarterly data, the cash conversion cycle has reached 108 days, driven by an inventory-heavy operational model that suggests potential inefficiencies in managing supply chain throughput relative to the company's historical performance and industry benchmarks for specialized medical device manufacturing.
The elevated DIO of 74 days indicates that UFPT is carrying significant inventory, which may be a strategic buffer against supply chain disruptions but currently acts as a drag on liquidity. Investors should watch for improvements in asset turnover, as the current level of 0.23 suggests that the company's capital-intensive manufacturing footprint is not yet fully optimized for rapid revenue conversion.
Based on an analysis of market sentiment, the most commonly misapplied metric for UFPT is the EV/EBITDA multiple, which often leads analysts to incorrectly categorize the firm as a commodity packaging provider rather than a specialized, high-barrier MedTech component manufacturer.
By utilizing standard packaging industry multiples, the market obscures the 'stickiness' of UFPT's sole-source status within FDA-validated medical devices. A more appropriate analytical framework would focus on the company's role as a critical sub-assembly partner, which warrants a valuation premium that reflects the high switching costs faced by its OEM customers.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UFPT stock.
UFP Technologies, Inc.'s current P/E ratio is 31.0x. The historical average is 17.6x. This places it at the 93th percentile of its historical range.
UFP Technologies, Inc.'s current EV/EBITDA is 19.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.1x.
UFP Technologies, Inc.'s return on equity (ROE) is 17.8%. The historical average is 10.3%.
Based on historical data, UFP Technologies, Inc. is trading at a P/E of 31.0x. This is at the 93th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
UFP Technologies, Inc. has 28.3% gross margin and 15.3% operating margin. Operating margin between 10-20% is typical for established companies.
UFP Technologies, Inc.'s Debt/EBITDA ratio is 1.3x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.